Gamma-glutamyltransferase and risk of hypertension: A systematic review and dose-responsemeta-analysis of prospective evidence

Journal of Hypertension

Volumn 33, Issue 12, 2015, Pages 2373-2381

  Kunutsor, Setor K ^a   Apekey, Tanefa A ^b   Cheung, Bernard M Y ^c,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^c Department of Medicine ^*  (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

dose response; gamma glutamyltransferase; high blood pressure; hypertension; meta analysis; prospective studies

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; BLOOD PRESSURE; RISK FACTOR;

BLOOD PRESSURE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERTENSION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84947025059     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000763     Document Type: Review

References (46)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
2. Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, et al. Associations of total and high-molecular-weight adiponectin with allcause and cardiovascular mortality in older persons: the cardiovascular health study. Circulation 2012; 126:2951-2961.
3. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:776-785.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127:e6-e245.
5. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288:1882-1888.
6. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282:2012-2018.
7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
8. Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol 2014; 24:809-816.
9. Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response metaanalysis. Int J Clin Pract 2015; 69:136-144.
10. Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 2014; 238:356-364.
11. Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Ikai E, et al. Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level. Hypertension 1991; 18:819-826.
12. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9:101-105.
13. Kissebah AH. Insulin resistance in visceral obesity. Int J Obes 1991; 15 (Suppl 2):109-115.
14. Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metabol Syndr 2014; 6:12.
15. Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis. PloS One 2012; 7:e48878.
16. Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N. Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol 2014; 180:763-775.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology. JAMA 2000; 283:2008-2012.
19. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011; Available from: http://www. ohri. ca/programs/clinical-epidemiology/oxford. asp.
20. Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent Form. Am J Epidemiol 1996; 144:610-621.
21. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135:1301-1309.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
23. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 175:66-73.
24. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006; 6:40-57.
25. Harrell FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer I 1988; 80:1198-1202.
26. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects metaanalyses. Stat Med 2010; 29:1282-1297.
27. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29:1037-1057.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21:1539-1558.
30. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18:2693-2708.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
33. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463.
34. Li M, McDermott R. Obesity albuminuria, and gamma-glutamyl transferase predict incidence of hypertension in indigenous Australians in rural and remote communities in northern Australia. J Hypertens 2015; 33:704-710.
35. Hwang JH, Shin JY, Chun B, Lee DH, Kim KY, Park WH, et al. Association between gamma-glutamyltransferase and hypertension incidence in rural prehypertensive adults. J Prev Med Public Health 2010; 43:18-25.
36. Persijn JP, van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem 1976; 14:421-427.
37. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38:263-355.
38. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 2011; 54:3003-3006.
39. Fall T, Hagg S, Magi R, Ploner A, Fischer K, Horikoshi M, et al. The role of adiposity in cardiometabolic traits: a mendelian randomization analysis. PLoS Med 2013; 10:e1001474.
40. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014; 236:7-17.
41. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005; 112:2078-2080.
42. Robinson D, Whitehead TP. Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening. Ann Clin Biochem 1989; 26 (Pt 5):393-400.
43. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178:327-330.
44. Shield KD, Gmel G, Kehoe-Chan T, Dawson DA, Grant BF, Rehm J. Mortality and potential years of life lost attributable to alcohol consumption by race and sex in the United States in 2005. PloS One 2013; 8:e51923.
45. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics; 1996. Available from: http://www. cdc. gov/nchs/data/ nhanes/nhanes3/cdrom/nchs/manuals/labman. pdf
46. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56:255-266.